Aarti Pharmalabs Ltd
NSE:AARTIPHARM
Operating Margin
Aarti Pharmalabs Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
IN |
A
|
Aarti Pharmalabs Ltd
NSE:AARTIPHARM
|
79.2B INR |
17%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
678.1B USD |
40%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
364.9B USD |
26%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
48%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
205.8B CHF |
33%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
181.3B CHF |
33%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
160.7B GBP |
24%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
193.3B USD |
34%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
11%
|
|
FR |
![]() |
Sanofi SA
PAR:SAN
|
116.8B EUR |
22%
|
Aarti Pharmalabs Ltd
Glance View
Aarti Pharmalabs Ltd. engages in the manufacture and sale of pharmaceutical and nutraceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 1,400 full-time employees. The company went IPO on 2023-01-30. The firm delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. The company has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Aarti Pharmalabs Ltd's most recent financial statements, the company has Operating Margin of 17.2%.